AlphaCrest Capital Management’s Myriad Genetics MYGN Stock Holding History

AlphaCrest Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30,238	Closed	-$577K	–	743
2022 Q3	$577K	Buy	+30,238	New	+$694K	0.04%	914
2022 Q2	–	Sell	-14,792	Closed	-$373K	–	1322
2022 Q1	$373K	Sell	14,792 -19,497	-57%	-$499K	0.02%	1028
2021 Q4	$946K	Buy	34,289 +11,570	+51%	+$335K	0.04%	822
2021 Q3	$734K	Sell	22,719 -14,067	-38%	-$467K	0.04%	754
2021 Q2	$1.13M	Buy	36,786 +25,775	+234%	+$745K	0.05%	608
2021 Q1	$335K	Buy	+11,011	New	+$312K	0.02%	973
2020 Q4	–	Sell	-17,152	Closed	-$224K	–	1220
2020 Q3	$224K	Buy	17,152 +6,874	+67%	+$87K	0.02%	999
2020 Q2	$117K	Buy	+10,278	New	+$146K	0.02%	876
2019 Q3	–	Sell	-8,712	Closed	-$242K	–	1301
2019 Q2	$242K	Buy	+8,712	New	+$246K	0.02%	924
2019 Q1	–	Sell	-9,300	Closed	-$270K	–	915
2018 Q4	$270K	Buy	+9,300	New	+$335K	0.08%	495

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

AlphaCrest Capital Management's MYGN Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Myriad Genetics (MYGN) in Q4 2022, closing a stake of 30,238 shares — an estimated $577K sold.

AlphaCrest Capital Management first reported a position in MYGN in Q4 2018 and held it in 10 quarters. The position peaked at $1.13M in Q2 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2022.

AlphaCrest Capital Management reported no remaining Myriad Genetics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 30,238 Myriad Genetics shares in Q4 2022, an estimated $577K.
AlphaCrest Capital Management first reported a position in Myriad Genetics in Q4 2018 and held it in 10 quarters.
AlphaCrest Capital Management's Myriad Genetics position peaked at $1.13M in Q2 2021.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.